ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0015

CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Abstract Number: 2073

Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Abstract Number: 2602

Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Abstract Number: 1852

Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Abstract Number: 0116

Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI
Abstract Number: 0733

Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study
Abstract Number: 0496

Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Abstract Number: 0855

Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Abstract Number: 1070

Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Abstract Number: 1029

Cervical cancer screening rates in Korean women of childbearing age with systemic lupus erythematosus
Abstract Number: 1094

Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Abstract Number: 0355

Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Abstract Number: 1897

Changes in SLE Mortality During and After the COVID-19 Pandemic
Abstract Number: 2210

Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
Abstract Number: 2280

Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].